34^th Euro-Global Summit on Cancer Therapy & Radiation Oncology July 25-27, 2019 | Park Inn by Radisson Hotel & Conference Centre London Heathrow Bath Road Heathrow Middlesex UB70DU

Dr. Hyoung K. Lee is Associate Professor and Chair of Nuclear Engineering at Missouri University of Science and Technology. Dr. Lee has his expertise in radiation detection and imaging. He has worked in teaching hospitals as a medical physicist and has also been a faculty member in academia since receiving his PhD from the University of California at Berkeley. His research area includes radiation detector design and characterization, advanced radiation sources, advanced imaging systems using x-ray, gamma ray or neutron, algorithms for CT reconstruction, image processing, image analysis, and application of deep learning for medical imaging. He has successfully conducted many research projects that covered a wide spectrum of radiation detection and imaging technologies, from development of radiation detectors to development of image enhancement algorithms (some of which were transferred to industry). His current research includes development of flat-panel x-ray sources, compact x-ray tubes for stationary cardiac CT and switchable radioisotopes for imaging and other applications. He has published more than one-hundred forty peer-reviewed publications and edited a book chapter in his field of research. He has also given twenty-five invited lectures and one-hundred and nine abstracted talks.

His research area includes radiation detector design and characterization, advanced radiation sources, advanced imaging systems using x-ray, gamma ray or neutron, algorithms for CT reconstruction, image processing, image analysis, and application of deep learning for medical imaging

Ozden Altundag, MD, graduated from Ankara University Medical School in 1993. She trained in Internal Medicine and Medical Oncology at the University of Hacettepe, School of Medicine, in Ankara, Turkey. She has been a clinical postdoctoral fellow at Thoracic & Head and Neck Cancer Medicine at University of Texas MD Anderson Cancer Center, in Houston, USA between 2004-2006. She has been practicing Medical Oncology since 2008 in Baskent University Ankara Hospital as a faculty member. She is spesifically interested in lung cancer, gynecologic cancer and immunotherapy. She is a members of Baskent Gynecologic Oncology Tumor Board, American Society of Clinical Oncology, The International Association for the study of Lung Cancer (IASLC), Turkish Society of Gynecologic-Oncology, Turkish Society of Lung Cancer. Sh ehad gynecological and lung cancer presentations at both international and national conferences. She has been conducting more than 10 international lung and gynecological cancer clinical studies. She had 117 international publications and 75 international abstracts.

Medical Oncology

Dr. CHEN Yangchao is affiliated to School of Biomedical Sciences, CUHK . Dr. CHEN Yangchao is currently providing services as Associate Professor. Dr. CHEN Yangchao has authored and co-authored multiple peer-reviewed scientific papers and presented works at many national and International conferences. Dr. CHEN Yangchao contributions have acclaimed recognition from honourable subject experts around the world. Dr. CHEN Yangchao is actively associated with different societies and academies. Dr. CHEN Yangchao academic career is decorated with several reputed awards and funding. Dr. CHEN Yangchao research interests include Identification of novel diagnostic markers and therapeutic targets for digestive cancers including pancreatic cancer and liver cancer,Identification and characterization of long and short non-coding RNAs with critic roles in cancer,Identification of cancer associated genes using large scale genetic perturbation screen such as CRISPR/CAS9.

Identification of novel diagnostic markers and therapeutic targets for digestive cancers including pancreatic cancer and liver cancer,Identification and characterization of long and short non-coding RNAs with critic roles in cancer,Identification of cancer associated genes using large scale genetic perturbation screen such as CRISPR/CAS9.

Kadri graduated from Hacettepe University Faculty of Medicine in 1990. He completed his specialty training at Hacettepe University Faculty of Medicine, Department of Internal Medicine in 1995 and his specialty training in 1999 at the same institution's Medical Oncology Unit. He became Associate Professor in 2000 and Professor in 2007. Between 2004 and 2006, she worked as a visiting scholar at the MD Anderson Cancer Center in Houston, Texas. He worked as the director of Hacettepe University Health Sciences Institute in 2013 and Hacettepe University Cancer Institute in 2013-2016, and Head of Department of Internal Medicine and Hacettepe University Oncology Department between 2013-2015.

Breast Medical Oncology

Dr. Mohammed Jawed is a radiologist in Syracuse, New York and is affiliated with Upstate University Hospital. He received his medical degree from Dow University of Health Sciences and has been in practice for more than 20 years. He is one of 55 doctors at Upstate University Hospital who specialize in Radiology.

Intervnetional oncology includes Hepatic chemoembolization, radioembolization Radiofrequency ablation

Dr Mari Aparici, MD is a Clinical Professor at Stanford University. She is a Nuclear Physician with residencies in both Europe (Barcelona) and US (Stanford), and with Molecular imaging fellowships from Stanford University. She is a physician-scientist in the development of Molecular Imaging. She has more than 20 years of clinical and research experience in the field, more than 10 years of a leadership position as Chief Nuclear Medicine at the San Francisco VAMC as part of her prior appointment as a UCSF faculty member, and now as Head of the Theranostics and Nuclear Therapies program at Stanford University. She has published more than 100 papers in reputed journals, has been serving as an editorial board member of reputed journals, has been PI of NIH and non-NIH grants and serves as a member of several to committees at her University and several Societies.

Clinical Focus on Radiology & Nuclear Medicine

Olivier E. Pardo graduated from the Faculty of Pharmacy Paris-V, France where he was awarded a Doctorate in Industrial Pharmacy (1997). He then completed his PhD in Biochemistry and Molecular Biology at Imperial College-London (2002). He obtained post-doctoral experience in the laboratory of Prof. Julian Downward at the CRUK-London Research Institute where he worked on the regulation of apoptotic cell death and cell migration. In 2006, he created the Cellular Regulatory Networks lab at Imperial College, Department of Surgery and Cancer. His team focuses on understanding the molecular mechanisms underlying chemo-resistance and metastasis in lung and other cancers.

Focuses on understanding the molecular mechanisms underlying chemo-resistance and metastasis in lung and other cancers